Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
Recruiting
Observational Study
Anal Cancer
Anal Carcinoma
Anal Squamous Cell Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 205 (estimated)
- Sponsor
- Herlev Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Biopsy-verified anal cancer
* Eligible for curative intended radiotherapy
* Written and oral consent
Exclusion Criteria:
* Other malignant disease within the past 5 years (excluding basal cell carcinoma)
Contacts